Generic

Mylan, Pfizer Settle Generic Viagra ANDA Litigation

Apr 14, 2015

Nasdaq

Mylan has announced that its subsidiaries have reached an agreement with Pfizer to settle patent litigation relating to Mylan's ANDA filed with the U.S. FDA for Sildenafil Citrate Tablets, or generic Viagra.

Pfizer's patent for Viagra expires in 2020. As per the agreement, Mylan will be able to launch its generic in the U.S. December 2017 or sooner under certain conditions. Mylan currently sells its Sildenafil Citrate in 11 European countries.

Read the Nasdaq press release